• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    PACS Group Announces Appointment of Evelyn Dilsaver to Serve as Independent Board Director

    5/13/24 7:31:00 PM ET
    $HQY
    $QDEL
    $TPX
    Real Estate
    Real Estate
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $HQY alert in real time by email

    PACS Group, Inc. (NYSE:PACS) ("PACS" or the "Company") announced today that Evelyn Dilsaver has been appointed to serve as a member of its Board of Directors. "We're thrilled to have Evelyn join our board," said Jason Murray, PACS Chairman and CEO. "She has great experience as an accounting and finance professional, not to mention her work on the boards of several other public companies. She'll bring added perspective and expertise to the board as we work to guide PACS going forward."

    "I'm excited to join the PACS Board and assist the company in continuing its mission to provide quality skilled nursing care. I look forward to great things ahead for the company," added Ms. Dilsaver.

    Ms. Dilsaver also serves on the boards of directors of Tempur Sealy International (NYSE:TPX), HealthEquity, Inc. (NASDAQ:HQY) and QuidelOrtho (NASDAQ:QDEL). Ms. Dilsaver was President and Chief Executive Officer of Charles Schwab Investment Management from July 2004 until September 2007. Prior to that, she held various senior management positions with The Charles Schwab Corporation. Ms. Dilsaver is a certified public accountant and holds a B.S. degree in accounting from California State University-Hayward.

    Ms. Dilsaver is an independent director under applicable NYSE and SEC rules. Her appointment now makes the PACS Board of Directors majority independent. Ms. Dilsaver's committee appointments will be considered at a later date.

    About PACS Group

    PACS Group, Inc. is a holding company investing in post-acute healthcare facilities, professionals, and ancillary services. Founded in 2013, PACS Group is one of the largest post-acute platforms in the United States. Its independent subsidiaries operate over 200 post-acute care facilities across nine states serving over 20,000 patients daily.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240513694766/en/

    Get the next $HQY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HQY
    $QDEL
    $TPX

    CompanyDatePrice TargetRatingAnalyst
    QuidelOrtho Corporation
    $QDEL
    5/7/2026$12.50Buy → Hold
    Jefferies
    HealthEquity Inc.
    $HQY
    4/9/2026$105.00Market Perform → Outperform
    BMO Capital Markets
    HealthEquity Inc.
    $HQY
    1/9/2026$89.00Neutral → Sell
    Goldman
    HealthEquity Inc.
    $HQY
    12/9/2025$118.00Overweight
    Barclays
    HealthEquity Inc.
    $HQY
    11/13/2025$100.00Market Perform
    BMO Capital Markets
    QuidelOrtho Corporation
    $QDEL
    10/7/2025$33.00Buy → Neutral
    Citigroup
    HealthEquity Inc.
    $HQY
    5/22/2025$105.00 → $112.00Outperform
    RBC Capital Mkts
    QuidelOrtho Corporation
    $QDEL
    5/8/2025$44.00Hold → Buy
    Jefferies
    More analyst ratings

    $HQY
    $QDEL
    $TPX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    QuidelOrtho downgraded by Jefferies with a new price target

    Jefferies downgraded QuidelOrtho from Buy to Hold and set a new price target of $12.50

    5/7/26 8:02:07 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    HealthEquity upgraded by BMO Capital Markets with a new price target

    BMO Capital Markets upgraded HealthEquity from Market Perform to Outperform and set a new price target of $105.00

    4/9/26 8:22:37 AM ET
    $HQY
    Real Estate

    HealthEquity downgraded by Goldman with a new price target

    Goldman downgraded HealthEquity from Neutral to Sell and set a new price target of $89.00

    1/9/26 8:49:40 AM ET
    $HQY
    Real Estate

    $HQY
    $QDEL
    $TPX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    One in Three Americans Delay Medical Care Due to Cost, HealthEquity Research Finds

    DRAPER, Utah, June 08, 2026 (GLOBE NEWSWIRE) -- Healthcare affordability remains a significant pressure point for American workers, with more than one in three delaying or avoiding care due to cost, according to new research from HealthEquity (NASDAQ:HQY), the nation's largest independent health savings account (HSA) custodian by account volume. The findings, released today as part of HealthEquity's second Healthcare Affordability Pulse, show how these pressures are shaping care decisions, workplace productivity, and financial preparedness across American households. HealthEquity's Spring 2026 survey found that healthcare-specific pressures show no signs of easing. A recent Gallup poll ci

    6/8/26 11:56:57 AM ET
    $HQY
    Real Estate

    QuidelOrtho and Allo Hope Foundation Join Forces to Advance Education, Connection and Early Testing for Alloimmunized Pregnancies

    SAN DIEGO, June 2, 2026 /PRNewswire/ -- QuidelOrtho, a global leader in diagnostic innovation, and the Allo Hope Foundation, a nonprofit dedicated to supporting families and clinicians managing maternal alloimmunization, announced a new collaboration focused on improving prenatal care through education, early testing and stronger connections between laboratory providers, clinicians and patients. Maternal red blood cell alloimmunization is a serious, often misunderstood condition that can pose significant risks to the child during pregnancy. Red cell antibodies can cross the placenta and destroy fetal and neonatal red blood cell

    6/2/26 7:12:00 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    HealthEquity Reports First Quarter Ended April 30, 2026 Financial Results; Raises Guidance

    Increases Repurchase Program by $1.0 Billion Highlights of the first quarter include: Net income increased 29% to $69.4 million, and net income margin increased to 20% from 16% last year.Adjusted EBITDA increased 17% to $164.5 million, and Adjusted EBITDA margin increased to 46% from 42% last year.Revenue increased 7% to $354.6 million.Net income per diluted share rose 34% to $0.82 from $0.61 one year ago, and non-GAAP net income per diluted share increased 28% to $1.24.Total HSA Assets grew 19% to $37.1 billion.Returned $123.0 million to shareholders through stock repurchases. DRAPER, Utah, May 28, 2026 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ:HQY) ("HealthEquity" or the "Company

    5/28/26 4:01:00 PM ET
    $HQY
    Real Estate

    $HQY
    $QDEL
    $TPX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, CHIEF COMMERCIAL OFFICER Fiore Michael Henry sold $298,490 worth of shares (3,142 units at $95.00) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 59,113 units (SEC Form 4)

    4 - HEALTHEQUITY, INC. (0001428336) (Issuer)

    6/2/26 5:03:25 PM ET
    $HQY
    Real Estate

    Director Strobeck Matthew was granted 6,829 shares, increasing direct ownership by 25% to 34,604 units (SEC Form 4)

    4 - QuidelOrtho Corp (0001906324) (Issuer)

    6/2/26 4:11:11 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Widder Kenneth J was granted 6,829 shares, increasing direct ownership by 18% to 43,890 units (SEC Form 4)

    4 - QuidelOrtho Corp (0001906324) (Issuer)

    6/2/26 4:10:48 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $HQY
    $QDEL
    $TPX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Chief Financial Officer Busky Joseph M. bought $79,742 worth of shares (3,370 units at $23.66) (SEC Form 4)

    4/A - QuidelOrtho Corp (0001906324) (Issuer)

    2/19/26 4:18:05 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Strobeck Matthew bought $239,586 worth of shares (10,000 units at $23.96), increasing direct ownership by 56% to 27,775 units (SEC Form 4)

    4 - QuidelOrtho Corp (0001906324) (Issuer)

    2/13/26 4:20:08 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chief Financial Officer Busky Joseph M. bought $79,742 worth of shares (3,370 units at $23.66) (SEC Form 4)

    4 - QuidelOrtho Corp (0001906324) (Issuer)

    2/13/26 12:44:31 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $HQY
    $QDEL
    $TPX
    SEC Filings

    View All

    SEC Form 144 filed by HealthEquity Inc.

    144 - HEALTHEQUITY, INC. (0001428336) (Subject)

    5/29/26 4:23:30 PM ET
    $HQY
    Real Estate

    SEC Form 10-Q filed by HealthEquity Inc.

    10-Q - HEALTHEQUITY, INC. (0001428336) (Filer)

    5/28/26 4:04:25 PM ET
    $HQY
    Real Estate

    HealthEquity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - HEALTHEQUITY, INC. (0001428336) (Filer)

    5/28/26 4:03:03 PM ET
    $HQY
    Real Estate

    $HQY
    $QDEL
    $TPX
    Leadership Updates

    Live Leadership Updates

    View All

    QuidelOrtho Corporation Completes Acquisition of LEX Diagnostics

    – Marks a Milestone in QuidelOrtho's Plans to Accelerate Growth in Point-of-Care Molecular Diagnostics –– Expands Portfolio with Ultra-Fast PCR Platform Designed to Deliver Results in Approximately Ten Minutes or Less –– Company Expects to Initiate U.S. Commercial Launch of the LEX VELO System Later This Year –SAN DIEGO, April 20, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, announced today it has completed the acquisition of LEX Diagnostics ("LEX") for cash consideration of approximately $100 million. The LEX VELO System received U.S. Food and Drug Administration ("FDA") 510(k) clearance and

    4/20/26 7:12:00 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    HealthEquity Appoints Sanford Health CEO Bill Gassen to Board of Directors

    DRAPER, Utah, March 30, 2026 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ:HQY) ("HealthEquity" or the "Company"), the largest independent health savings account (HSA) custodian by account volume and a leader in consumer-directed benefits (CDB), today announced that William ‘Bill' Gassen, president and chief executive officer of Sanford Health, has been elected to its board of directors (the "Board") effective March 26, 2026. He will also serve on the Audit and Risk Committee and Talent, Compensation and Culture Committee of the Board. His appointment expands the Board to 10 directors, eight of whom are independent. "Bill brings deep insight into how care is delivered, how it is financed

    3/30/26 8:30:00 AM ET
    $HQY
    $OSCR
    Real Estate
    Medical Specialities
    Health Care

    Nathaniel Sisitsky Joins QuidelOrtho as Chief Legal Officer

    SAN DIEGO, March 24, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, is pleased to announce the appointment of Nathaniel "Nate" Sisitsky as its new Chief Legal Officer, effective March 23, 2026. He will report to Brian Blaser, President and Chief Executive Officer, and will lead QuidelOrtho's global legal, compliance and corporate governance functions. Mr. Sisitsky brings more than 25 years of legal and governance experience advising public companies across life sciences and technology sectors.

    3/24/26 7:00:00 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $HQY
    $QDEL
    $TPX
    Financials

    Live finance-specific insights

    View All

    HealthEquity Reports First Quarter Ended April 30, 2026 Financial Results; Raises Guidance

    Increases Repurchase Program by $1.0 Billion Highlights of the first quarter include: Net income increased 29% to $69.4 million, and net income margin increased to 20% from 16% last year.Adjusted EBITDA increased 17% to $164.5 million, and Adjusted EBITDA margin increased to 46% from 42% last year.Revenue increased 7% to $354.6 million.Net income per diluted share rose 34% to $0.82 from $0.61 one year ago, and non-GAAP net income per diluted share increased 28% to $1.24.Total HSA Assets grew 19% to $37.1 billion.Returned $123.0 million to shareholders through stock repurchases. DRAPER, Utah, May 28, 2026 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ:HQY) ("HealthEquity" or the "Company

    5/28/26 4:01:00 PM ET
    $HQY
    Real Estate

    QuidelOrtho Reports First Quarter 2026 Financial Results

    ― LEX Diagnostics Acquisition Expected to Accelerate Growth in Point-of-Care Molecular Diagnostics ―― Key Product Launches in U.S. and International Markets Expected to Drive Future Growth ―― Company Updates Full-Year 2026 Financial Guidance ― SAN DIEGO, May 5, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today announced financial results for the first quarter ended March 29, 2026. Key First Quarter 2026 Results:(all comparisons are to the prior year period)Total revenue was $620

    5/5/26 4:05:00 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    HealthEquity Announces First Quarter Earnings Release Date and Investor Conference Schedule

    DRAPER, Utah, May 05, 2026 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ:HQY) ("HealthEquity" or the "Company"), the largest independent health savings account (HSA) custodian by account volume and a leader in consumer-directed benefits (CDB), today announced plans to release financial results for its first quarter of fiscal 2027, after the close of regular stock market trading on Thursday, May 28, 2026. Following the news release, HealthEquity management will host a conference call for investors on Thursday, May 28, 2026, at 4:30 p.m. Eastern Time during to review the Company's first quarter results. HealthEquity First Quarter Fiscal Year 2027 Results Conference CallDate:May 28, 2026Time

    5/5/26 4:01:00 PM ET
    $HQY
    Real Estate

    $HQY
    $QDEL
    $TPX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by QuidelOrtho Corporation

    SC 13G/A - QuidelOrtho Corp (0001906324) (Subject)

    12/6/24 10:11:24 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13D/A filed by QuidelOrtho Corporation

    SC 13D/A - QuidelOrtho Corp (0001906324) (Subject)

    11/21/24 5:10:19 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13G/A filed by QuidelOrtho Corporation

    SC 13G/A - QuidelOrtho Corp (0001906324) (Subject)

    11/14/24 1:28:35 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care